<DOC>
	<DOCNO>NCT01907906</DOCNO>
	<brief_summary>The purpose study evaluate radiolabeled recovery survival autologous red blood cell ( RBC ) , derive Mirasol-treated fresh whole blood ( WB ) , store leukoreduced packed RBC ( LR-pRBC ) , re-infused healthy adult subject</brief_summary>
	<brief_title>Inactivation Whole Blood With Mirasol</brief_title>
	<detailed_description>This feasibility level study conduct assess recovery survival autologous , radiolabeled leukoreduced packed red blood cell ( LR-pRBC ) derive fresh whole blood ( WB ) unit treat Mirasol System Whole Blood ( Mirasol System ) store 21 day 1-6°C.1</detailed_description>
	<criteria>Eligible whole blood donor Age ≥ 18 year , either sex Able commit study followup schedule Subjects must adequate bilateral antecubital venous access WB collection followup blood draw Negative screen test panel infectious disease Subjects childbearing potential ( female male ) must agree use effective contraceptive course study per site guideline Subjects must agree report adverse event ( AEs ) require reporting period Negative direct antiglobulin test ( DAT ) subject 's RBC Negative indirect antiglobulin test ( IAT ) subject 's serum Inclusion radiolabeled reinfusion LRpRBC Day 21 ( evaluate day , prior , reinfusion ) : Maintenance healthy status Negative direct antiglobulin test ( DAT ) subject 's RBC ( fresh ) Negative indirect antiglobulin test ( IAT ) subject 's serum ( fresh ) versus autologous store LRpRBC Negative serum urine pregnancy test females Any serious medical illness and/or therapy , include : abnormal bleeding episode , clot bleed disorder , evidence anemia , myocardial infarction , uncontrolled hypertension , heart disease , surgery bleeding complication , epilepsy major surgery ( general spinal anesthesia ) within last 6 month Pregnant nursing female ; For woman childbearing potential , negative serum urine pregnancy test time WB donation reinfusion require Unable give inform consent Participation currently , within last 12 month , another investigational trial would potentially interfere analysis investigation ( e.g. , pharmaceutical ) Have receive accumulate radiation dose would exclude study accord local radiation safety limit establish institution Inability comply protocol opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Pathogen reduction technology</keyword>
</DOC>